Issues in diagnostic testing and monitoring in HIV/viral hepatitis co-infection.
Co-infection with HIV and hepatitis B (HBV)/ hepatitis C virus (HCV) occurs commonly due to similar routes of transmission. Both hepatotropic viruses can cause a severe clinical picture in HIV-infected individuals with rapid progression of liver disease, cirrhosis and increased mortality. Fortunately, treatment options of HBV and HCV are becoming well established and may have a clinical impact in slowing disease progression. This, coupled with the fact that highly active antiretroviral therapy (HAART) has increased the life expectancy of HIV-infected patients stresses the importance of management of concurrent illnesses such as HBV and HCV infection, taking into consideration pharmacokinetic interaction with components of HAART regimens.
Dervisevic
Samir
S
Department of Virology, Royal Free and University College Medical School, 46 Cleveland Street, London W1T 4JF, UK.
Pillay
Deenan
D
D000914:Antibodies, Viral / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D006678:HIV / Q000254:growth & development; D015658:HIV Infections / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D016133:Polymerase Chain Reaction; D011933:Reagent Kits, Diagnostic
D000914:Antibodies, Viral; D000998:Antiviral Agents; D004279:DNA, Viral; D011933:Reagent Kits, Diagnostic